Axinn Team Prevails for Alvogen in Suboxone Antitrust Litigation
August 26, 2020
In another victory on behalf of Axinn’s client Alvogen, a district court affirmed a previous court ruling that both Alvogen and Dr. Reddy’s Laboratories can move forward with antitrust counterclaims against Indivior. The counterclaims arise from a dispute over generic versions of Suboxone, Indivior’s opioid addiction treatment. The Axinn team included Matt Becker and Ted Mathias.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
DC Bar: The DOJ's New Antitrust Whistleblower Rewards Program: An Overview and the Road Ahead
Speaking Engagement
Antitrust
Informa Antitrust Midwest 2026
Speaking Engagement
Antitrust
Axinn Partner Scott Eisman Selected as Rising Star in New York Law Journal’s 2026 New York Legal Awards
Awards & Recognitions
Litigation & Trials
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2026
Sponsorship
Right to Repair Alert: Deere & Company Reaches Settlement with FTC, States
Axinn Viewpoints
Antitrust
Ten Axinn Attorneys Recognized by 2025 Empire State Counsel Program
Awards & Recognitions
What’s Up? Enforcement Updates From the Middle East and Africa
Podcast
Antitrust
AHLA Annual Meeting & In-House Counsel Program
Sponsorship
Antitrust
Lexology In-Depth: Intellectual Property and Antitrust (2026)
Byline Articles
Intellectual Property
Tracking The Rare 'Quick Look' Win In FTC's Zillow-Redfin Suit
Byline Articles
Antitrust

